J. Sarlo

HIV-Infected Patients Receiving Lopinavir/Ritonavir-Based Antiretroviral Therapy Achieve High Rates of Virologic Suppression Despite Adherence Rates Less Than 95%

J. Shuter, B. Zingman, Jonathan Shuter, 2007, Journal of acquired immune deficiency syndromes.

Modified directly observed therapy (MDOT) for injection drug users with HIV disease.

P. Jatlow, J. Arnsten, M. Gourevitch, 2002, The American journal on addictions.

Sequential Antiretroviral Adherence Measurement Using Electronic Bottle Cap Monitors in a Cohort of HIV-Infected Adults

J. Shuter, B. Zingman, R. Rode, 2012, Journal of the International Association of Physicians in AIDS Care.

Specific sequences commonly found in the V3 domain of HIV-1 subtype C isolates affect the overall conformation of native Env and induce a neutralization-resistant phenotype independent of V1/V2 masking.

S. Zolla-Pazner, M. Gorny, James E. Robinson, 2014, Virology.

Tuberculosis in anergic HIV-infected drug users.

H. Abeles, S. Farber, J. Sarlo, 1993, JAMA.

Occurrence of Selective Ritonavir Nonadherence and Dose-Staggering in Recipients of Boosted HIV-1 Protease Inhibitor Therapy

J. Shuter, B. Zingman, R. Rode, 2009, HIV clinical trials.